At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results of the multi-arm phase 1 TATTON trial, which evaluated the mutant-selective EGFR tyrosine kinase inhibitor, AZD9291, combined with MEDI4736 (anti-PD-L1 monoclonal antibody), savolitinib (MET inhibitor) or selumetinib (MEK1/2 inhibitor) in patients with EGFR-mutant lung cancer.
TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer
10th July 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now